Related Experiment Video

Updated: Jan 9, 2026

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
09:37

Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

Published on: March 5, 2017

13.5K

Erratum: Genome Editing in Patient iPSCs Corrects the Most Prevalent USH2A Mutations and Reveals Intriguing Mutant

Carla Sanjurjo-Soriano, Nejla Erkilic, David Baux

    Molecular Therapy. Methods & Clinical Development
    |December 11, 2025
    PubMed

    Abstract:

    [This corrects the article DOI: 10.1016/j.omtm.2019.11.016.].

    More Related Videos

    Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation
    09:51

    Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

    Published on: February 2, 2016

    14.1K
    CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
    08:31

    CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation

    Published on: June 20, 2019

    14.6K

    Related Experiment Videos

    Last Updated: Jan 9, 2026

    Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development
    09:37

    Genome Editing and Directed Differentiation of hPSCs for Interrogating Lineage Determinants in Human Pancreatic Development

    Published on: March 5, 2017

    13.5K
    Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation
    09:51

    Establishment of Genome-edited Human Pluripotent Stem Cell Lines: From Targeting to Isolation

    Published on: February 2, 2016

    14.1K
    CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
    08:31

    CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation

    Published on: June 20, 2019

    14.6K

    Related Concept Videos

    iPS Cell Differentiation01:22

    iPS Cell Differentiation

    3.0K
    The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
    3.0K
    EPS and iPS Cells in Disease Research01:21

    EPS and iPS Cells in Disease Research

    3.3K
    Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
    3.3K

    Articles linked to this work by shared authors, journal, and citation graph.

    Deep Learning for Diagnosis of Choroideremia and USH2A-Associated Rod-Cone Dystrophy Using Macular OCT Volumes.

    Ophthalmology science·2026

    Building a National Interoperable Rare Eye Disease Data Warehouse: Methodological Framework and Implementation Report From the French Rare Eye Disease Database (FREDD) Initiative.

    JMIR medical informatics·2026

    Clinical and molecular features of PRCD-associated retinopathy.

    Acta ophthalmologica·2026

    Phenotypic Variations in a Large Family with Dominant Optic Atrophy Related to a Novel OPA1 Deletion.

    Ophthalmology science·2026

    Generation of an induced pluripotent stem cell line, LGMi002-A, from a Bardet-Biedl Syndrome patient with a BBS5 homozygous pathogenic variant.

    Stem cell research·2026

    Interim 2025/26 LP.8.1 vaccine effectiveness estimates against COVID-19 from the Canadian Sentinel Practitioner Surveillance Network (SPSN): insights into possible impact of influenza and other respiratory virus co-circulation.

    Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin·2026

    Characterization and quantitation of baculoviral DNA in rAAV vectors produced in Sf9 cells.

    Molecular therapy. Methods & clinical development·2026

    In vivo delivery of a fluorogenic antisense oligonucleotide into human leukocytes in a humanized mouse model system.

    Molecular therapy. Methods & clinical development·2026

    Development of high-throughput analytical methods for characterization and quantitation of rAAV genome integrity.

    Molecular therapy. Methods & clinical development·2026

    Morphological changes induced by buffer exchange during preparation of mRNA-lipid nanoparticles occur in a stepwise manner as pH is elevated.

    Molecular therapy. Methods & clinical development·2026

    Targeted inhibition of ELANE expression using adenine base editing to treat severe congenital neutropenia.

    Molecular therapy. Methods & clinical development·2025

    AAV-PHP.eB achieves superior neuronal transduction over AAV9 in pigtail macaques following intracerebroventricular administration.

    Molecular therapy. Methods & clinical development·2025

    Single-stage microscopic and endoscopic resection of spatially separate meningiomas through a single craniotomy.

    Surgical neurology international·2026

    Correction: Novel Behavior of the 2019 Novel Coronavirus With Invasion of the Cardiac Conduction System in the Young.

    Cureus·2026

    Integration of artificial intelligence into pharmacovigilance: A systematic review.

    Research in social & administrative pharmacy : RSAP·2026

    Recent advances in antioxidant nanozymes for the treatment of inflammatory bowel disease.

    Nanomedicine : nanotechnology, biology, and medicine·2026

    The expression window as a safety parameter for mRNA medicines.

    Biochemical pharmacology·2026

    Delivery architectures for oligonucleotide therapeutics in genetic and rare diseases: GalNAc-based hepatocyte targeting and extrahepatic translation.

    Journal of controlled release : official journal of the Controlled Release Society·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us